Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Boatsetter sets sail with $27.8m series A
Stanford Daper Fund-backed Boatsetter has increased its series A to at least $27.8m with $10m from investors including WestCap Group and Valor Equity Partners.
Glycomine digs up $33m series B
Mission Bay Capital has backed a series B round for orphan diseases drug developer Glycomine, which also attracted Novo, Asahi Kasei Pharma and Chiesi.
SmartNews has the scoop on $28m series E
SmartNews, co-founded by University of Tokyo researcher Ken Suzuki, is valued at $1.1bn following a $28m series E round led by Japan Post Capital.
AgroSavfe nurtures series C
Biopesticide developer AgroSavfe, a VIB spinout, has raised more than $38m in series C funding from investors including Qbic.
Wyoming gains Momentus for $25.5m
University of Wyoming Foundation has contributed to a round for inter-orbital satellite shuttle service provider Momentus which brought its overall funding haul to $34m.
Pyxis picks up Bayer for $22m round
University of Chicago immuno-oncology spinout Pyxis Oncology has been backed by corporate investment vehicle Leaps by Bayer in its first funding round.
Trefoil triumphs with $28m
Florida State University cornea repair drug developer Trefoil Therapeutics added funding from investors including subsidiaries of Aju Corporation and Access Biotechnology to bring its total to $33.2m.
CureApp secures $20m funding
Keio Innovation Initiative contributed to a $20m round that increased the total funding for medical access app developer CureApp, partially based on Keio University research, to nearly $39m.

Other News

Axial Biotherapeutics realigns series B
Taiho Ventures has supplied a $10m extension for Caltech spinout Axial Biotherapeutics’ series B, bringing the total to $35m.
Everactive deciphers $30m
University of Virginia-founded batteryless industrial IoT monitor developer Everactive was previously known as PsiKick, and has now raised a total of $63m in equity funding.
Imcyse immunises $31.4m
KU Leuven's autoimmune disease therapy developer Imcyse, which is targeting type 1 diabetes, has raised close to $39m in equity and debt financing in its latest effort.
Corporates align with Purigen in series B round
Roche participated in the Agilent Technologies-led round, which will fund the launch of Stanford spinout Purigen's isotachophoresis-based DNA and RNA sample preparation platform.
Sense Photonics grasps $26m series A
Lidar technology developer Sense Photonics has emerged from stealth with $26m in series A funding from investors co-led by the UC-backed Congruent Ventures.
OncoMyx hits $25m
OncoMyx Therapeutics was co-founded by ASU's Grant McFadden and will use the series A funding to advance the development of its lead asset aimed at several indications of cancer.

Editor's Picks

Tel Aviv partners with Tata
Tel Aviv University announces $20m commercialisation fund with Tata Industries.
UK graphene research nets $35m backing
Cell Medica raises $26.5m
Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.
Revolymer sticks to AIM in IPO
Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.
test reg